Last reviewed · How we verify
Birch pollen allergoid
Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization.
Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization. Used for Birch pollen-induced allergic rhinitis and/or allergic asthma.
At a glance
| Generic name | Birch pollen allergoid |
|---|---|
| Also known as | specific immunotherapy |
| Sponsor | Allergopharma GmbH & Co. KG |
| Drug class | Allergen immunotherapy (allergoid) |
| Target | Birch pollen allergens (Bet v 1 and related epitopes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
The allergoid is created by chemically modifying birch pollen proteins to reduce their allergenic potency while preserving immunogenicity. When administered in escalating doses, it trains the immune system to tolerate birch pollen exposure, shifting the immune response from IgE-mediated allergic reactions toward regulatory T cell responses and IgG-blocking antibodies. This mechanism underlies allergen immunotherapy (AIT) and aims to provide long-term clinical and immunological tolerance.
Approved indications
- Birch pollen-induced allergic rhinitis and/or allergic asthma
Common side effects
- Local injection site reactions (itching, swelling, erythema)
- Oral allergy syndrome or local oral symptoms
- Systemic allergic reactions (mild to moderate)
- Headache
Key clinical trials
- Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen (PHASE2)
- Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens (PHASE3)
- Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma (PHASE2)
- Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine (PHASE2)
- Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Birch pollen allergoid CI brief — competitive landscape report
- Birch pollen allergoid updates RSS · CI watch RSS
- Allergopharma GmbH & Co. KG portfolio CI